Timeline
2014
The Institute for Surgical Research reports that the AAJT-S is the only junctional tourniquet to prevent collateral flow
2017
Institute for Surgical Research and 59th Med Wing complete 8 studies showing the AAJT-S is equivalent to Zone 3 REBOA
2018
Feasibility study shows 100% survival in Non-Compressible Torso Hemorrhage (NCTH) model utilizing the new Torso Plate™ in conjunction with the AAJT-S
2018
59th Med Wing publishes research showing AAJT-S application in traumatic cardiac arrest improves survivability to 83%
2018
AAJT-S suggested as management solution for postpartum hemorrhage in resource limited environments
2019
US Special Operations Medics find the AAJT-S is the only junctional tourniquet to remain effective when performing rescue drags and casualty movement during simulated combat environments
2019
Swedish Researchers publish data in Journal of Trauma and Acute Care Surgery showing the AAJT-S can effectively provide a bridge and transition to REBOA from the point of wounding and injury
2019
59th Med Wing publishes research showing AAJT-S in cardiac arrest improves efficiency of chest compressions in CPR
2019
The GEN 2 AAJT-S is released. No more ratchet system and is lighter, faster to apply and more stable than prior versions
2020
Australian study published in Resuscitation demonstrated that 22% of Traumatic Cardiac Arrest patients had a return of spontaneous circulation (ROSC) when the AAJT-S was applied
2020
Compression Works grows and welcomes medical device veteran Scott Dodson as President and CEO
2021
Compression Works Increases EMS Market Distribution Capabilities Across the United States
2022
Comprehensive Scientific Study Demonstrates Compression Works' AAJT-S Device Useful in Traumatic Cardiac Arrest and Non-Compressible Truncal Hemorrhage Patients
2023
